MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU)

Michael Sun,Charlene Thomas,Benedict Ho,Junaid Niaz,Jones T. Nauseef,Joseph R. Osborne,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil H. Bander,Scott T. Tagawa

MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU)

2021

Michael Sun
Charlene Thomas
Benedict Ho
Junaid Niaz
Jones T. Nauseef
Joseph R. Osborne
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa

INTRODUCTION AND OBJECTIVE:177Lu-PSMA is a promising investigational treatment for men with mCRPC. Optimal selection and biomarkers remain to be defined. Here, we report a combined analysis of men ...

Keywords:

Oncology
Prostate cancer
Glutamate carboxypeptidase II
Medicine
Internal medicine
long term follow up
prognostic factor
castration resistant
Selection (genetic algorithm)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations